Stock Price Quote

ASTEC LIFESCIENCES LTD.

NSE : ASTECBSE : 533138ISIN CODE : INE563J01010Industry : Pesticides & AgrochemicalsHouse : Godrej
BSE901.253.85 (+0.43 %)
PREV CLOSE ( ) 897.40
OPEN PRICE ( ) 900.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 184
TODAY'S LOW / HIGH ( )895.20 933.00
52 WK LOW / HIGH ( )826.15 1540
NSE902.353.5 (+0.39 %)
PREV CLOSE( ) 898.85
OPEN PRICE ( ) 900.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 902.35 (10)
VOLUME 1717
TODAY'S LOW / HIGH( ) 891.15 908.50
52 WK LOW / HIGH ( )825.05 1541.65
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 25-01 1994
Management Info
- Chairman - Managing Director
Registered Office

Address Godrej One, 3rd Floor,Pirojshanagar, Eastern Express Highway ,Vikhroli (East),
Mumbai,
Maharashtra-400079

Phone 022-25188010

Email astecinfo@godrejastec.com

Website www.godrejastec.com

Registrars Details
Bigshare Services Pvt Ltd
Office No S6-2, 6th Floor, Pinnacle Business Park,Next to Ahura Centre, Mahakali Caves Road,Andheri (E),Mumbai
Listing : BSE, NSE

NEWS

12Feb Appointment of CEO
Inter alia, approved:- (a) RE-APPOINTMENT OF MR. ANURAG ROY (DIN: 07444..
11Jan Astec Lifesciences informs about compl
Astec Lifesciences has enclosed compliance certificate received from Big..
23Aug Astec Lifesciences raises Rs 49 crore
Astec Lifesciences has raised Rs 49 crore through the allotment of 4,900..
02Aug Astec Lifesciences informs about discl
Astec Lifesciences has informed that the exchange has received the discl..
11Apr Astec LifeSciences launches R&D Center
Astec LifeSciences has launched its new advanced research and developmen..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit-243.47255.19
Gross Profit -322.47 348.48
Operating Profit -174.29893
Net Sales 507.946281.66

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Bhagiradha Chem (BSE)
peergroup  1794.00 (3.13%)
M.Cap ( in Cr)1866.74
Dhanuka Agritech (BSE)
peergroup  1046.00 (1.73%)
M.Cap ( in Cr)4767.49
Punjab Chem. & Corp (BSE)
peergroup  1046.80 (0.95%)
M.Cap ( in Cr)1283.61
Rallis India (BSE)
peergroup  262.35 (3.70%)
M.Cap ( in Cr)5101.89
Bayer CropScience (BSE)
peergroup  5656.05 (0.15%)
M.Cap ( in Cr)25419.47

Shareholding Pattern

MUTUAL FUNDS/UTI 8.77%
PROMOTERS 66.75%
NON-INSTITUTION 22.23%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Astec Lifesciences Ltd.

Astec Lifesciences Ltd. was incorporated in the year 1994. Its today's share price is 901.25. Its current market capitalisation stands at Rs 1767.28 Cr. In the latest quarter, company has reported Gross Sales of Rs. 6312.32 Cr and Total Income of Rs.6412.02 Cr. The company's management includes Nandkumar Dhekne, Anjali Rajesh Gupte, RR Govindan, Anurag Roy, Burjis Godrej, Tejashree Pradhan.

It is listed on the BSE with a BSE Code of 533138 , NSE with an NSE Symbol of ASTEC and ISIN of INE563J01010. It's Registered office is at Godrej One, 3rd Floor,Pirojshanagar, Eastern Express Highway ,Vikhroli (East)Mumbai-400079, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are BSR & Co LLP, PM Kathariya & Co, Shah & Kathariya

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.